Eli Lilly's weight-loss drug no longer in shortage - Search News

Zepbound Tops Wegovy for Weight Loss

Eli Lilly says its weight loss drug Zepbound outperformed Wegovy in a study

Eli Lilly said its drug Zepbound led to greater weight reduction than rival Novo Nordisk's Wegovy in a head-to-head randomized controlled trial.

Hosted on MSN · 6h

The Weight-Loss Battle That Could Rattle Eli Lilly's $100 Billion Market

An age-old battle in pharmaceuticals could further rattle Eli Lilly stock and its potential $100 billion market in weight-loss drugs.

CNBC on MSN · 1d

Eli Lilly's Zepbound causes greater weight loss than Novo Nordisk's Wegovy in head-to-head trial

Zepbound’s greater weight loss is a huge advantage for Eli Lilly, which is competing with Novo Nordisk for a larger share of the weight loss drug market.

FDA Still Undecided About Shortage Status of Lilly’s Tirzepatide

Pending the FDA’s decision, compounding pharmacies will remain free to make and market versions of the blockbuster ...

health.wusf.usf.edu15d

Drugmakers and pharmacists battle over who gets to make obesity drugs

Ozempic and similar drugs for Type 2 diabetes and weight loss are in such ... Novo Nordisk and Eli Lilly are moving ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results